drugset / Trial / NCT02669615

Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

NCT02669615 ↗

Phase 2 Completed 24 enrolled Medical College of Wisconsin
NaSingle-groupOpen-labelTreatment

Summary

This study is a single-center, open-label study of high-dose Melphalan HCl (hydrochloric acid) for injection (propylene glycol-free Melphalan) conducted in 24 patients, who have symptomatic multiple myeloma and qualify for autologous stem-cell transplantation (ASCT). There will be three distinct evaluation periods in this trial: a pretreatment period, a study period and a follow-up period.

Timeline

Start
2016-11-01
Primary completion
2017-06-09
Completion
2017-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule 200 mg/m2 —

Indications